EE262 Cost-Consequence Analysis of Cabozantinib in Combination With Nivolumab in Treatment of First-Line Advanced Renal Cell Carcinoma in Germany: A Payer Perspective
Abstract
Authors
D Gultyaev E Kaltenbach M Lothgren J Stiefel J Kisro